scholarly journals Pharmacotherapy in Pediatric Neurogenic Bladder Intravesical Botulinum Toxin Type A

ISRN Urology ◽  
2012 ◽  
Vol 2012 ◽  
pp. 1-6
Author(s):  
Cristian Sager ◽  
Carol Burek ◽  
Victor Durán ◽  
Juan Pablo Corbetta ◽  
Santiago Weller ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Neurogenic Bladder ◽  
Botulinum Toxin A ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Bladder Pressure ◽  
Urinary Continence ◽  
Novel Therapy ◽  
Bibliographic Search

When the neurogenic bladder is refractory to anticholinergics, botulinum toxin type A is used as an alternative. The neurotoxin type A reduces bladder pressure and increases its capacity and wall compliance. Additionally, it contributes to improving urinary continence and quality of life. This novel therapy is ambulatory with a low incidence of adverse effects. Due to its transitory effect, it is necessary to repeat the injections in order to sustain its therapeutic effect. In these review article we talk about Mechanism of Action, Indications, effects, administration and presentations of the Botulinum Neurotoxin Type A in pediatric patients. Also, we make references to controversial issues surrounding its use. A bibliographic search was done selecting articles and revisions from Pubmed. The key words used were botulinum toxin A, neurogenic bladder, and children. The search was limited to patients younger than 18 years of age and reports written in English in the past ten years.

scholarly journals Successful treatment of lower eyelid epiblepharon by injection of botulinum toxin A in patients under two years of age

2013 ◽  
Vol 5 (2) ◽  
pp. 177-181 ◽  
Author(s):  
CY Chen ◽  
Angel Nava-Castaneda
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Botulinum Toxin Type A ◽  
Clinical Signs ◽  
Signs And Symptoms ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Lower Eyelid ◽  
Rank Test ◽  
Orbicularis Muscle

Introduction: Epiblepharon is characterized by a cutaneous horizontal fold adjacent to the lid margin. Some cases showed spontaneous resolution, others required surgical treatment. We propose a medical treatment with botulinum toxin type A (BTX-A). Objective: To provide clinical evidence of the usefulness of botulinum toxin type A (BTX-A) in patients with lower eyelid epiblepharon. Subjects and methods: This was a prospective, non-randomized, nonmasked study. Patients with lower eyelid epiblepharon with corneal eyelash contact were included in the study. The scale proposed by Khwarg & Lee (1997) was used to assess the epiblepharon clinical evaluation. A single dose of 12.5 IU of BTX-A (Dysport ®) was directly injected into the medial pre-tarsal orbicularis muscle region in the lower eyelid. Patients were evaluated before the injection and at 1, 4, 12 and 24 weeks after the injection. We performed descriptive statistics and Wilcoxon Signed Rank Test, comparing prior injection measurements to post injection measurements at the 24th week. A p < 0.05 was considered statistically significant. Each eye was separately analyzed. Results: Fourteen eyes of seven Hispanic patients were treated, five female and two male. The mean age was 8.4 months (4 - 14 months). The height of the skin-fold, the area of the cornea touched by the cilia and the symptoms score improved after the first week of BTX-A injection and remained so until the end of study (p < 0.05). No major complications were noted. Conclusion: The effect of a single 12.5 IU injection of BTX-A (Dysport ®) into the medial orbicularis muscle portion in the lower eyelid epiblepharon patients successfully improves the clinical signs and symptoms. Nepal J Ophthalmol 2013; 5(10): 177-181 DOI: http://dx.doi.org/10.3126/nepjoph.v5i2.8709

Lack of Ultrastructural Detrusor Changes Following Endoscopic Injection of Botulinum Toxin Type A in Overactive Neurogenic Bladder

2004 ◽  
Vol 46 (6) ◽  
pp. 784-791 ◽  
Author(s):  
A. Haferkamp ◽  
B. Schurch ◽  
A. Reitz ◽  
U. Krengel ◽  
J. Grosse ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Neurogenic Bladder ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Endoscopic Injection

scholarly journals Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity

2020 ◽  
Vol 33 (11) ◽  
pp. 761
Author(s):  
Alexandre Camões- Barbosa ◽  
Inês Mendes Ribeiro ◽  
Luisa Medeiros
Keyword(s):  
Botulinum Toxin ◽  
Upper Limb ◽  
Botulinum Toxin A ◽  
Neuromuscular Block ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Deltoid Muscle ◽  
Botulinum Toxin Type ◽  
Toxin A ◽  
Limb Weakness

Botulinum toxin type A has been approved for spasticity management in poststroke patients. The adverse effects are generally of two types: those related to local injection; and those related to the systemic effects from spread of the toxin. Contralateral weakness after botulinum toxin A treatment is a rarely reported adverse effect. We report the case of a 33-year-old female who had been receiving regular injections of incobotulinum toxin A due to spasticity of the right limbs after a hemorrhagic stroke. A switch was made to abobotulinum toxin A with an overall conversion ratio of 1:3.83. The patient presented contralateral upper limb paresis, especially of the deltoid muscle, in the second week post-injection. The electroneuromyography showed neuromuscular block due to botulinum toxin A. She recovered completely after eight months. A switch between different formulations of botulinum toxin type A should prompt caution when carrying out unit conversions. Distant side effects may appear, including paresis in the contralateral limbs.

746 HISTHOLOGICAL FEATURES IN BLADDER WALL IN CHILDREN WITH NEUROGENIC BLADDER DYSFUNCTION AFTER BOTULINUM TOXIN TYPE A INJECTIONS

2010 ◽  
Vol 183 (4S) ◽  
Author(s):  
Maria Paola Pascali ◽  
Giovanni Mosiello ◽  
Renata Boldrini ◽  
Maria Letizia Salsano ◽  
Armando Marciano ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Neurogenic Bladder ◽  
Bladder Dysfunction ◽  
Botulinum Toxin Type A ◽  
Bladder Wall ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Neurogenic Bladder Dysfunction

Botulinum Toxin Type a for Frey's Syndrome: A Preliminary Prospective Study

1998 ◽  
Vol 107 (1) ◽  
pp. 52-55 ◽  
Author(s):  
Ollivier Laccourreye ◽  
Luca Muscatelo ◽  
Carole Naude ◽  
Brigitte Bonan ◽  
Daniel Brasnu
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Frey’S Syndrome ◽  
Frey's Syndrome ◽  
Valuable Treatment ◽  
Intracutaneous Injection

Fourteen patients with severe Frey's syndrome (occurring after conservative parotidectomy) managed with intracutaneous injection of botulinum toxin type A were prospectively evaluated. Results were analyzed for effectiveness, complications, and adverse effects. Complications were not encountered. The only adverse effect noted was a temporary and slight partial paresis of the upper lip of 3 months' duration in 2 patients. Permanent paresis was not encountered. Frey's syndrome was always controlled within 2 days following the intracutaneous injection of botulinum toxin A. Frey's syndrome recurrence was not encountered with a follow-up duration that varied from 3 to 9 months (mean follow-up 7 months). This preliminary report confirmed that in patients who have Frey's syndrome after conservative parotidectomy, the intracutaneous injection of botulinum toxin is a valuable treatment option that should be further investigated.

Sign in / Sign up

Export Citation Format

Share Document